Publication | Closed Access

Cost-Effectiveness Analysis of Extended Duration Anticoagulation with Rivaroxaban to Prevent Recurrent Venous Thromboembolism

ThrombosisPulmonary EmbolismVenous ThrombosisCost-effectiveness AnalysisExtended Duration AnticoagulationPatient SafetyHematologyOutcomes ResearchRecurrent Venous ThromboembolismPharmacotherapyMedicineAnticoagulantEmergency MedicineAnesthesiology